Experimental COVID shot made via egg-based technology elicits a higher antibody proportion than mRNA vax
An experimental COVID-19 vaccine produced with technology based on a decades-old method, eliminated virus-neutralizing antibodies in a higher proportion than the amount induced by mRNA immunizations, a Phase 1 clinical trial has found.
The investigational vaccine was developed in New York City and tested in Thailand where the shots were produced using a form of egg-based technology. The fact that researchers are still racing to develop new COVID-19 vaccines highlights an ongoing need, especially in low- and middle-income countries—and for good reason.
A surprising slew of omicron subvariants has emerged since 2021. Last year, omicron spawned a dizzying number of subvariants: BA.5, BQ.1, and BQ.1.1. By January of this year, a new omicron subvariant called XBB. 1.5 was sweeping across the United States and beyond.
“A large number of vaccines for SARS-CoV-2 have been developed and licensed,” asserted Juan Manuel Carreño, writing with a team of researchers in Science Translational Medicine. As a research scientist in the microbiology department at Mount Sinai’s Icahn School of Medicine in New York